《大行報告》麥格理料華虹(01347.HK)未來業績受12吋晶圓廠拖累 維持「跑輸大市」評級
麥格理發表研究報告,指出華虹半導體(01347.HK)第二季業績表現好壞參半,8寸晶圓廠的表現不錯,使用率達100%,毛利率28%,較首季的21%有所增長;而12寸晶圓的收入增長繼續緩慢,收入僅900萬美元,稅前虧損3,400萬美元。
根據公司指引,第三季收入按年下跌1%至2.36億美元,毛利率介乎22至24%,較第二季的26%有所下跌。該行仍認為公司正在執行正確的策略,相信及至2022年12寸晶圓的收入有望翻倍。然而,預計在未來四至六個季度12寸晶圓的虧損持續,導致盈利表現欠佳。
麥格理維持華虹半導體「跑輸大市」投資評級,12個月目標價為12.6元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.